Nom du produit:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
IUPAC Name:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
- CAS：2657617-90-6
- Formule moléculaire：C12H14BF4NO2
- Pureté：95%+
- Numéro de catalogue：CM1075242
- Poids moléculaire：291.05
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2657617-90-6
- Formule moléculaire:C12H14BF4NO2
- Point de fusion:-
- Code SMILES:FC=1C(F)=C(F)C(B2OC(C)(C)C(O2)(C)C)=C(N)C1F
- Densité:
- Numéro de catalogue:CM1075242
- Poids moléculaire:291.05
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Boronic Acids and Esters
- Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
- Boronic Acid For Sale
- Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Column Infos
- Glecirasib
- On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.
Recherche 
+86 21 5895 0110 
